BioSpace News Archive

Italian ReiThera Srl., German LEUKOCARE AG, and Belgian Univercells S.A., announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19.

Avadel Pharma announced positive topline data from its pivotal Phase III REST-ON clinical trial of FT218 for excessive daytime sleepiness and cataplexy in patients with narcolepsy.

About 70% of AD patients have symptoms of agitation, which is marked by emotional distress, aggressive behaviors, disruptive irritability and loss of inhibition.

Company enters next development phase with management expansion and implementation of a Strategic and Scientific Advisory Board

NANO-X IMAGING LTD (www.nanox.vision) (“Nanox” or the “Company”), an innovative medical-imaging technology company, announces today a partnership agreement with the Nobel Peace Prize-nominated Hadassah Hospital in Jerusalem, to use the Nanox ARC system on site for developing novel early-detection and screening protocols to promote global preventive healthcare practices.

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the crucial pyrogenicity testing that is required by the U.S. Food and Drug Administration (FDA) of the encapsulation material used to manufacture PharmaCyte’s Cell

Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced that APCER Life Sciences has confirmed the safety profile of Endari®, Emmaus’ prescription grade L-glutamine oral powder for the treatment of sickle cell disease.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was dosed in Cohort 4 of the ongoing OPTIC Phase 1 clinical trial for ADVM-022 for the treatment of wet age-related macular degeneration (AMD). Patients in Cohort

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Jonathan Freve, CPA, as its Chief Financial Officer (CFO).

Study Presented in Virtual Session at AACR Annual Meeting Provides Evidence of Potential for Zotatifin to Drug an Important Class of Oncogene Drivers